0000899243-17-012361.txt : 20170508
0000899243-17-012361.hdr.sgml : 20170508
20170508203716
ACCESSION NUMBER: 0000899243-17-012361
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170504
FILED AS OF DATE: 20170508
DATE AS OF CHANGE: 20170508
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Altimmune, Inc.
CENTRAL INDEX KEY: 0001326190
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 202726770
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 19 FIRSTFIELD ROAD
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
BUSINESS PHONE: 2406541450
MAIL ADDRESS:
STREET 1: 19 FIRSTFIELD ROAD
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
FORMER COMPANY:
FORMER CONFORMED NAME: PHARMATHENE, INC
DATE OF NAME CHANGE: 20071016
FORMER COMPANY:
FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP
DATE OF NAME CHANGE: 20050505
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Roberts M Scot
CENTRAL INDEX KEY: 0001705905
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32587
FILM NUMBER: 17824142
MAIL ADDRESS:
STREET 1: 19 FIRSTFIELD RD., SUITE 200
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-05-04
0
0001326190
Altimmune, Inc.
NASDAQ:ALT
0001705905
Roberts M Scot
19 FIRSTFIELD ROAD, SUITE 200
GAITHERSBURG
MD
20878
0
1
0
0
Chief Scientific Officer
Stock Option (option to buy)
0.08
2017-05-04
4
A
0
55120
A
2017-05-04
2022-12-05
Common Stock, par value $0.0001
55120
55120
D
Stock Option (option to buy)
0.59
2017-05-04
4
A
0
8956
A
2023-12-04
Common Stock, par value $0.0001
8956
8956
D
Stock Option (option to buy)
2.59
2017-05-04
4
A
0
8956
A
2024-12-02
Common Stock, par value $0.0001
8956
8956
D
Stock Option (option to buy)
13.38
2017-05-04
4
A
0
11235
A
2026-04-07
Common Stock, par value $0.0001
11235
11235
D
Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger.
The option is currently exercisable to purchase 6,716 shares of the Issuer's common stock, par value $0.0001 ("Common Stock"). The remaining portion of the option will vest on 12/4/2017.
The option is currently exercisable to purchase 4,477 shares of Common Stock. An additional 25% of the option will vest on each of 12/3/2017 and 12/3/2018.
The option is currently exercisable to purchase 2,809 shares of Common Stock. An additional 25% of the option will vest on each of 3/2/2018, 3/2/2019, and 3/2/2020.
/s/ Ori Solomon, Attorney in fact for M. Scot Roberts
2017-05-08